Uso de amiodarona oral como tratamiento crónico en un paciente con hepatitis fulminante previa por amiodarona intravenosa

López-Gómez, David; Nicolás, Joan; Frigola, José María; Manito, Nicolás; Esplugas, Enric

doi:10.1016/s0300-8932(99)74896-7

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Polysorbate 80 is a cosolvent used at a concentration of 10% to solubilize the lipophilic amiodarone (48). This hypothesis is supported by the observation that two of the patients described in the literature and case 3 described here showed no or only mild liver function test abnormalities with oral amiodarone preceding intravenous administration (34,37). Furthermore, six patients (including case 3 in our series) recovered after stopping intravenous amiodarone, despite immediately starting therapy with oral amiodarone (30,31,37,44).…”

Section: Discussionsupporting

confidence: 82%

“…This hypothesis is supported by the observation that two of the patients described in the literature and case 3 described here showed no or only mild liver function test abnormalities with oral amiodarone preceding intravenous administration (34,37). Furthermore, six patients (including case 3 in our series) recovered after stopping intravenous amiodarone, despite immediately starting therapy with oral amiodarone (30,31,37,44). Another two patients were rechallenged later with oral amiodarone and none of them showed any hepatotoxic effects (33,41).…”

Section: Discussionsupporting

confidence: 82%

“…Another two patients were rechallenged later with oral amiodarone and none of them showed any hepatotoxic effects (33,41). In contrast, three patients developed a second episode of acute hepatocellular injury after reexposure to intravenous amiodarone (37,41,43). Alternatively, it cannot be excluded that the hepatotoxic effects associated with intravenous loading with amiodarone are related to higher amiodarone plasma and possibly liver concentrations after intravenous compared with oral administration.…”

Section: Discussionmentioning

confidence: 97%

See 2 more Smart Citations

Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature*

Bravo

Drewe

Schlienger

et al. 2005

Critical Care Medicine

View full text Add to dashboard Cite

Amiodarone is a highly effective antiarrhythmic agent for the treatment and prevention of atrial and ventricular arrhythmias. Acute liver damage after intravenous amiodarone, possibly induced by the solubilizer polysorbate 80, is rare but potentially harmful. Amiodarone loading should therefore be adapted to the necessity of an immediate effect of the drug, and liver function should be monitored closely in critically ill patients. Oral maintenance therapy with amiodarone is possible, even in patients who developed liver disease during intravenous loading.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature*

Bravo

Drewe

Schlienger

et al. 2005

Critical Care Medicine

View full text Add to dashboard Cite

show abstract

Hepatitis tóxica aguda de instauración precoz por amiodarona intravenosa

Galilea

Sánchez

García

et al. 2002

Gastroenterología y Hepatología

View full text Add to dashboard Cite

Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature

Nasser

Larsen²,

Waanbah³

et al. 2013

DHPS

View full text Add to dashboard Cite

Amiodarone is a benzofuran class III antiarrhythmic drug used to treat a wide spectrum of ventricular tachyarrhythmias. The parenteral formulation is prepared in polysorbate 80 diluent. We report an unusual case of acute elevation of aminotransaminase concentrations after the initiation of intravenous amiodarone. An 88-year-old Caucasian female developed acute hepatitis and renal failure after initiating intravenous amiodarone for atrial fibrillation with a rapid ventricular response in the setting of acutely decompensated heart failure and hepatic congestion. Liver transaminases returned to baseline within 7 days after discontinuing the drug. Researchers hypothesized that this type of injury is related to liver ischemia with possible superimposed direct drug toxicity. The CIOMS/RUCAM scale identifies our patient’s acute hepatitis as a highly probable adverse drug reaction. Future research is needed to understand the mechanisms by which hyperacute drug toxicity occurs in the setting of impaired hepatic perfusion and venous congestion.

show abstract

Uso de amiodarona oral como tratamiento crónico en un paciente con hepatitis fulminante previa por amiodarona intravenosa

Cited by 3 publications

References 5 publications

Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature*

Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature*

Hepatitis tóxica aguda de instauración precoz por amiodarona intravenosa

Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature

Contact Info

Product

Resources

About